Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1342-1351, 2005. First published June 16, 2005; 10.1373/clinchem.2004.046086
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.046086v1
51/8/1342    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sölétormos, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sölétormos, G.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:1342-1351.)
© 2005 American Association for Clinical Chemistry, Inc.

Review

Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice

György Sölétormos1,a, Axel Semjonow2, Paul E.C. Sibley3, Rolf Lamerz4, Per Hyltoft Petersen5, Walter Albrecht6, Peter Bialk7, Massimo Gion8, Frank Junker7, Hans-Peter Schmid9, Hein Van Poppel10 on behalf of the European Group on Tumor Markers1

1 Department of Clinical Biochemistry, Hillerød Hospital, Hillerød, Denmark.
2 Department of Urology, Prostate Center, University of Münster, Münster, Germany.
3 Euro/DPC Limited, Gwynedd, United Kingdom.
4 Department of Medicine II, Grosshadern Hospital, University of Munich, Munich, Germany.
5 NOKLUS, Norwegian Quality Improvement of Primary Care Laboratories, Division For General Practice, University of Bergen, Bergen, Norway.
6 Department of Urology, Rudolfstiftung, Vienna, Austria.
7 Roche Diagnostics GmbH, Mannheim, Germany.
8 Centre for the Study of Biological Markers of Malignancy, General Regional Hospital Campo SS., Venice, Italy.
9 Department of Urology, Cantonal Hospital, St. Gallen, Switzerland.
10 Department of Urology, University Hospital of Leuven, Leuven, Belgium.

aAddress correspondence to this author at: Department of Clinical Biochemistry, Hillerød Hospital, Helsevej 2, 3400 Hillerød, Denmark. Fax 45-4824-0067; e-mail geso{at}fa.dk.

Background: The objectives of this study were to determine whether a single result for total prostate-specific antigen (tPSA) can be used confidently to guide the need for prostate biopsy and by how much serial tPSA measurements must differ to be significant. tPSA measurements include both analytical and biological components of variation. The European Group on Tumor Markers conducted a literature survey to determine both the magnitude and impact of biological variation on single, the mean of replicate, and serial tPSA measurements.

Methods: The survey yielded 27 studies addressing the topic, and estimates for the biological variation of tPSA could be derived from 12 of these studies.

Results: The mean biological variation was 20% in the concentration range 0.1–20 µg/L for men over 50 years. The biological variation means that the one-sided 95% confidence interval (CI) of the dispersion for a single tPSA result is ~33%. Three replicate samples with one analysis on each narrow the one-sided 95% CI for the mean concentration to ~20% and facilitate decisions on prostate biopsy. During monitoring of serial measurements, the change needed for significance is ~50% (P <0.05).

Conclusions: The biological variation of tPSA has implications for screening, diagnosis, and monitoring. Single measurements may not be sufficiently precise for screening and diagnosis. Replicate samples and calculation of the mean concentration may improve precision by reducing the dispersion. Monitoring of tPSA requires an estimate of either the change needed for significance or, alternatively, of the significance of the change.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Dednam, B. C. Vorster, and J. B. Ubbink
Biological Variation of Myeloperoxidase
Clin. Chem., January 1, 2008; 54(1): 223 - 225.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Stephan, M. Klaas, C. Muller, D. Schnorr, S. A. Loening, and K. Jung
Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update
Clin. Chem., January 1, 2006; 52(1): 59 - 64.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.